First developed for cancer immunotherapy, CARs demonstrated their feasibility in early pre-clinical studies in which CD4+FOXP3+ Treg specificity was redirected against antigen relevant to autoimmunity (36, 37). Here, CD4 is linked to Autoimmunity.